Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06154070 · ClinicalTrials.gov registry record

An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention

A clinical trial of Migraine Disorders, sponsored by Ki Health Partners..

Active
Registry status
10
Enrollment target
2
Study locations

NCT06154070: Active study of Migraine Disorders, sponsored by Ki Health Partners..

NCT06154070 is a study of Migraine Disorders that is active but no longer recruiting, run by Ki Health Partners.. The registered enrollment target is 10 participants, below the 315-participant average among 21 other Migraine Disorders trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06154070, a study of Migraine Disorders, is active but no longer recruiting, sponsored by Ki Health Partners..

ACTIVE NOT RECRUITING
Registry status
10 participants
Enrollment target
2
Study locations

Study Summary

This is a prospective, multi-center, unblinded study in patients with migraine (≥ 8 MMDs(monthly migraine days)/month) requiring preventive treatment. Enrolled patients will receive DAXXIFY (DAX/Doxibutlinumtoxin A)administered subcutaneously per the EEG paradigm (injection pattern). The safety and efficacy outcome measures will be assessed at selected dosing segments during the 24-week treatment phase as well as the Post Treatment (4 weeks). There are 2 sites in the U.S. participating, where a total of 20 patients will be enrolled.

Conditions Studied

Migraine Disorders

Interventions

  • DRUG DaxibotulinumtoxinA

Study Locations (2)

California

  • The Los Angeles Headache Center - Los Angeles

Connecticut

  • New England Institute For Clinical Research - Stamford

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2023-10-24
Est. Completion 2024-10
Ki Health Partners.

2 total trials

What the registry record for NCT06154070 still lists

NCT06154070 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 315-participant average among 21 other Migraine Disorders trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Migraine Disorders appearing as the primary indexed condition, and to 1 intervention - of which DaxibotulinumtoxinA is the first listed.

NCT06154070 reports a single indexed study location in California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06154070 about?

NCT06154070 is a clinical study titled "An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention". This is a prospective, multi-center, unblinded study in patients with migraine (≥ 8 MMDs(monthly migraine days)/month) requiring preventive treatment. Enrolled patients will receive DAXXIFY (DAX/Doxibutlinumtoxin A)administered subcutaneously per the EEG paradigm (injection pattern). The safety an...

What is the current status of trial NCT06154070?

This trial is currently active not recruiting. The enrollment target is 10 participants. The study started on 2023-10-24. Estimated completion is 2024-10.

What conditions does trial NCT06154070 study?

This clinical trial studies the following conditions: Migraine Disorders.

What interventions are being tested in trial NCT06154070?

The interventions under investigation include: DaxibotulinumtoxinA (DRUG).

Who is sponsoring clinical trial NCT06154070?

This trial is sponsored by Ki Health Partners., which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06154070 being conducted?

This trial has 2 study locations across California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Migraine Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06154070's enrollment target sits among peer trials

10 21st of 21 higher than 1 of 21 other Migraine Disorders trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Migraine Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06154070, the US trial registry maintained by the National Library of Medicine. NCT06154070 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.